A New Era in Psoriasis Treatment: How Biologics Precisely Defeat Psoriasis

Introduction

Psoriasis, commonly known as "psoriasis vulgaris," is a chronic inflammatory skin disease affecting approximately 125 million people worldwide. In China, the prevalence rate is about 0.47%, meaning over 6.5 million patients are living with erythema, scaling, and itching. Traditional treatments (such as topical corticosteroids, phototherapy, and methotrexate) have some efficacy but often face issues like unsustainable results and notable side effects. In recent years, the advent of biologics has completely transformed the treatment landscape, making "complete clearance of lesions" a realistic possibility. This article will systematically analyze the strategies for selecting biologics to help you navigate the treatment maze.

Biologics: Precision Targeting of Immune Pathways

Biologics are protein-based drugs produced through genetic engineering that can precisely block key inflammatory cytokines involved in the pathogenesis of psoriasis. Unlike traditional systemic drugs (such as methotrexate), biologics act like "smart missiles," targeting only specific pathways with minimal impact on normal cells, resulting in greater efficacy and fewer side effects.

Currently, several biologics have been approved globally, primarily falling into the following categories:

TNF-α inhibitors: Such as etanercept and infliximab, which are early representatives, effective but may induce anti-drug antibodies.

IL-12/23 inhibitors: Such as ustekinumab, targeting two key cytokines with durable efficacy.

IL-17 inhibitors: Such as secukinumab and ixekizumab, directly targeting the core pathogenic pathway, with rapid onset and high rates of lesion clearance.

IL-23 inhibitors: Such as guselkumab, offering greater specificity and lower injection frequency (every 8 weeks), with excellent long-term remission.

According to the 2023 International Psoriasis Council guidelines, for moderate-to-severe patients, IL-17 and IL-23 inhibitors are recommended as first-line biologics due to their superior efficacy and favorable safety profiles.

How to Choose the Right Biologic for You?

Choosing a biologic is not simply about "newer is better"; the following factors should be comprehensively considered:

Disease Severity: Assessed using the PASI score (Psoriasis Area and Severity Index). A PASI ≥10 or BSA ≥10% indicates moderate-to-severe disease, warranting consideration of biologics.

Comorbidities: If there are concurrent conditions such as arthritis, cardiovascular disease, or inflammatory bowel disease, specific targets should be prioritized. For example, IL-17 inhibitors are particularly effective when psoriatic arthritis is present; however, if Crohn's disease coexists, IL-17 inhibitors should be avoided as they may exacerbate the condition.

Route and Frequency of Administration: Some drugs require intravenous infusion (necessitating hospital visits), while others can be administered subcutaneously (at home). Ixekizumab is injected every 2 weeks initially, then monthly during maintenance; guselkumab is given every 8 weeks, offering greater convenience.

Insurance and Cost: Biologics are expensive, with annual costs ranging from 50,000 to 150,000 RMB. In China, many biologics have been included in medical insurance, significantly reducing out-of-pocket expenses. Additionally, some pharmaceutical companies offer patient assistance programs to alleviate financial burdens.

Before making a decision, it is recommended to undergo tuberculosis screening, hepatitis B and C testing, and other evaluations to rule out contraindications. Consult a professional dermatologist to develop an individualized plan based on your specific situation.

Full Treatment Process and Safety Monitoring with Biologics

A standard treatment protocol typically includes:

Baseline Assessment: Comprehensive physical examination, laboratory tests (complete blood count, liver and kidney function), and infection screening (tuberculosis, hepatitis, HIV).

Induction Phase: Initial dosing is more frequent, usually achieving significant improvement within 4–16 weeks. Secukinumab 300 mg is administered weekly for 5 weeks, then transitioned to the maintenance phase.

Maintenance Phase: Injections are given at fixed intervals, such as every 4 or 8 weeks, to maintain clearance of lesions long-term.

Efficacy Evaluation: Follow-up visits every 3–6 months, using objective measures such as PASI score and DLQI (Dermatology Life Quality Index).

Safety Monitoring: Regular checks of blood counts, liver and kidney function, and vigilance for infection risk. If severe infection, allergic reactions, or neurological symptoms occur, seek medical attention promptly.

According to clinical trial data, after 16 weeks of IL-17 inhibitor treatment, approximately 80% of patients achieve PASI 75 (≥75% improvement in lesions), and nearly half achieve PASI 90 (near-complete clearance). Long-term follow-up (5 years) shows stable efficacy and a low incidence of adverse events.

Beyond Biologics: Combination Therapy and Lifestyle

Biologics are not a panacea; combination therapy can enhance outcomes. For example, topical moisturizers can relieve dryness, and phototherapy can assist in clearing stubborn lesions. Additionally, lifestyle modifications are crucial:

Avoid Triggers: Infections (such as streptococcal pharyngitis), stress, smoking, and alcohol can induce or exacerbate psoriasis.

Healthy Diet: A Mediterranean diet (rich in fruits, vegetables, fish, and olive oil) helps reduce inflammation. Vitamin D supplementation may be beneficial.

Emotional Management: Psoriasis is associated with depression; seek psychological support if needed.

Remember, biologics are tools, and a healthy lifestyle is the foundation; combining both ensures long-term stability.

Advice for International Patients

For overseas patients considering treatment in China or remote consultations, MedBridge can provide the following assistance:

Remote Consultation: Connect with dermatology experts from top-tier hospitals in China via video for second opinions.

Treatment Plan Development: Based on your condition, medical history, and budget, select the most suitable biologic.

Follow-up Care: Assist in arranging regular follow-up visits, medication delivery, and safety monitoring.

Before traveling abroad for medical care, bring your previous medical records, medication history, and imaging data to help doctors quickly understand your situation. If you have specific questions, feel free to contact us or use the cost estimator tool to get an approximate budget. Although biologics are expensive, they can significantly improve quality of life and are a worthwhile investment in the long run. Psoriasis is not an incurable disease; with scientific treatment and firm confidence, you can fully regain healthy skin!